Airnergy Report by Dr. Nyjon Eccles
- May 2004
Dr Nyjon
Eccles BSc MBBS PhD MRCP
The Chiron Clinic
Harley St, London, England W1G 6AX
Abstract
Six volunteers were recruited for a study
of the effect of 4 sessions of 20 minute Airnergy sessions on
various physiological parameters, namely Heart Rate Variability
(HRV), Respiratory function in 2 asthma sufferers and Live blood
morphology.
There was a significant expansion of the
total HRV power during autonomic nervous system challenge indicating
a positive effect on physiological reserve capacity. Both asthmatics
demonstrated a 20% improvement in Peak Expiratory Flow Rate (PEFR)
and improved subjectively. There was a consistent increase in
white blood cell activity in all subjects as observed on Live
Blood Microscopy but with one exception, no change in red blood
cell morphology.
Introduction
Airnergy is a new process of oxygen therapies
whereby the oxygen content of the air is activated by a means
of Chemo-luminescence. It is thought that in this state the oxygen
is more available for biological processes.
Heart rate variability (HRV) is based on
the time difference between each heart beat (R-wave) i.e. the
beat-to-beat variability and is a useful non-invasive measure
of autonomic nervous system balance but more importantly an indicator
of the bodys reserve energy and its capacity to respond
to challenge. There has been unpublished research (Knopp, 2003)
demonstrating that Airnergy can produce an improvement in HRV
of 34% after only 20 minutes of treatment. One of the characteristics
of a healthy physiological system is greater response potential
to challenge and this result would suggest that in such a position
the system would be better able to respond to and compensate
for physiological stress and in general have better performance.
The aim of this small study was to try to replicate the above
findings with HRV and to look for other evidence of improved
physiological performance.
Objectives
To examine the effects of 4 days consecutive
20-minute treatments in 6 subjects using the Airnergy Professional
Plus apparatus on several physiological parameters of health
and wellbeing. These included live blood morphology, heart rate
variability and respiratory function.
Methods
Six volunteers were recruited to take part
in the trial. Four were female associates, 1 was a male associate
and the last was recruited by way of a PR agency and was known
to be an asthma sufferer. With the exception of two of them who
had mild and moderate asthma, the volunteers were not known to
suffer from any medical condition and were not taking any regular
medications.
Subjects were assessed in the following
ways:
1) By Live blood analysis, to look for
any visual effect on red blood cell morphology and white blood
cell activity.
2) Heart rate variability (measured by
Nerve Express), to observe any effect on autonomic nervous system
function and adaptability
3) Respiratory Function Tests, including
Peak Expiratory Flow Rate (PEFR), Forced Expiratory Volume at
1 second (FEV1) and Forced Vital Capacity (FVC). These tests
were only performed on the 2 patients with asthma.
4) Subjective effects
HRV equipment was only available for the
days 2 and 3 of the 4-day study. Two of the volunteers were asthma
sufferers, one with mild asthma using only a salbutamol inhaler
as required and the other with mild asthma and hayfever (to grass
pollen) required regular inhaled steroids. On days 1 to 4 subjects
had a spot of blood taken from a fingertip with the aid of a
lancet. This was repeated before and after 20 minutes (set at
100%) of Airnergy (Airnergy Professional Plus) treatment by way
of nasal cannula. On 2 days all subjects had their HRV assessed
both in the supine and upright positions by way of the Nerve
Express apparatus before and after Airnergy treatment. In addition,
the two asthma sufferers had lung function assessed as indicated
above.
Results
Average age of the 6 volunteers was 43.2
with a range of 27-59. There were 5 females and 1 male.
TP1U = Total Power upright before Airnergy
treatment,
TP2U = Total Power upright after Airnergy treatment
Total power is a measure of the amount of nervous system activity
that is available, similar to the amount of charge in a battery.
In the face of challenge to the autonomic nervous system (in
this case on standing from supine position to upright) there
was a significantly (p < 0.04) greater amount of total power
in the system after 20 minutes treatment with Airnergy than before
treatment. Respiratory Function
Subject |
PEFR
(l/min)
Before AE |
PEFR
(l/min)
After AE |
FEV1
(litres)
Before
AE |
FEV1
(litres)
After AE |
FVC
(litres)
Before AE |
FVC
(litres)
After AE |
ME |
|
|
|
|
|
|
Day 1 |
286 |
345 |
|
|
|
|
Day 2 |
279 |
328 |
2.08 |
2.19 |
2.22 |
2.20 |
Day 3 |
219 |
206 |
1.80 |
1.46 |
2.65 |
2.09 |
|
|
|
|
|
|
|
JK |
|
|
|
|
|
|
Day 1 |
412 |
436 |
|
|
|
|
Day 2 |
468 |
505 |
3.67 |
3.72 |
4.18 |
4.16 |
Day 3 |
517 |
519 |
|
|
|
|
In connection with the above formal measurements the following
comments were made by the 2 subjects involved:
ME, aged 38, female, mild asthmatic using bronchodilators on
average 4 to 5 times per day.
Comments:
Not having to use bronchodilator as much during the days of treatment.
Only needing to use bronchodilator once a day during the trial.
JK, aged 28, female, mild to moderate asthma and hayfever, on
regular inhaled steroids and bronchodilators twice per day.
Comments:
Breathing easier during night after first treatment, did not
need bronchodilator. Breathing better on waking after first treatment
when she would normally require bronchodilator. Before third
treatment had felt a little wheeziness and chest tightness during
the day due to hayfever but after treatment experienced a clear
chest with the disappearance of the chest tightness. Subject
had had fragmented sleep for 3 weeks prior to the trial but slept
well for 3 days during the trial.
Live Blood Analysis
(Red blood cell morphology and white blood cell activity)
Subject |
General
Observations |
Red Cell Morphology |
White Cell Activity |
DB
Age 59
Female |
Grade 1 to 2 rouleaux
No white cell cytoplasmic streaming or movement |
No change |
Day 2 and 3 â no change.By Day 4 there was
clear cytoplasmic streaming and movement. |
AP
Age 56
Female |
Grade 1 to 2 rouleaux
No white cell cytoplasmic streaming or movement |
No change |
Day 2 to 4 both cytoplasmic streaming and movement were observed |
BM
Age 35
Female |
Grade 1 to 2 rouleaux
No white blood cell cytoplasmic streaming or movement |
No change |
Day 2 to 4 white cell cytoplasmic streaming was prominent. |
ME
Age 38
Female
Asthmatic |
Grade 1 to 2 rouleaux
White blood cells static |
No change |
Day 2 - no change.
Day 3 - cytoplasmic streaming before and after treatment.
Day 4 streaming after treatment only. |
JK
Age 28
Female
Asthmatic/
Hayfever |
Grade 2 rouleaux.
White blood cells static. |
Day 2 and 3 - no change. Day 4 -noticeably much less red cell
rouleaux (Grade 1) |
Day 2 - cytoplasmic streaming seen. Increased immediately
after treatment.
Day 3 â Static white cells before treatment
with increased streaming and movement after treatment.
Day 4 - Streaming and movement before treatment with increases
in both after treatment. |
Rouleaux = Red blood cell clumping. Grade 0 = no rouleaux, Grade
1 = a few random red cell clumps, Grade 2 = prominent red blood
cell clumping, Grade 3 = red blood cells mainly in rouleaux.
White blood cells: Cytoplasmic streaming refers to visible movement
of granules within the cytoplasm. Movement refers to clear pseudopodic
active and progressive movement.
Other Subjective results
(Each statement was made by a different subject)
Fatigue noted after first treatment. Some dizziness, tiredness,
headache and disconnected feelings with subsequent treatments.
Hayfever symptoms stopped, no sneezing due to cat fur allergy
whilst on the trial. Less nasal irritation. Much more energy
noted.
Sleepiness after first treatment. Sometimes awakes with headache
but during trial no usual headache and consistently much deeper
sleep.
After first treatment increased urinary frequency and bowel movement
noted. This did not persist. Much more energy noted thereafter.
Discussion and Conclusions
Six subjects of average age 43.2 (range of 27-59) were investigated
to determine the effect of the Airnergy treatment given for 20
minutes on 4 consecutive days. Heart rate variability (HRV) is
a useful non-invasive measure of autonomic nervous system balance
but more importantly an indicator of the bodyâs
reserve energy and its capacity to respond to challenge. HRV
was observed to improve significantly (p<0.04) in the presence
of autonomic nervous system stress after Airnergy treatment.
This was manifest as an increase in the total power measured
in the autonomic nervous system. This finding suggests that Airnergy
was somehow able to increase the reserve capacity of the autonomic
nervous system. Increased flexibility and dispersion in autonomic
nervous system is consistent with an enhanced capacity to handle
physiological stress.
Two of the 6 subjects were asthma sufferers. In one, there was
a 20% increase in peak expiratory flow rate (PEFR) immediately
after treatment and in the other a cumulative increase in PEFR
with each treatment reaching a 26% increase at the end of the
4 treatments. There did not appear to be any changes in Forced
Expiratory Volume in 1 second (FEV1) or Forced vital capacity
(FVC) in either subject. Both subjects felt that their breathing
improved during the treatments and both realised a reduction
in the need to use their bronchodilator inhalers. The finding
that PEFR increased would argue that the treatment was doing
something to reduce airway resistance. A further study is needed
in order to ascertain the exact mechanism of this action.
Finally, an interesting observation was made on live blood microscopy.
One subject who had particularly prominent red blood cell rouleaux
had a noticeable reduction of this phenomenon after 3 treatments.
In the other subjects there was no observable effect on red blood
cell morphology. In all subjects however, there was a tendency
towards increased white blood cell activity after successive
Airnergy treatments. This was particularly noticeable as most
subjects began the trial with static white blood cells demonstrated
by absence of cytoplasmic and cell membrane movement. It is not
clear what the significance of this finding is or whether this
would represent better immune competence âin
vivoâ. A further study to measure specific
markers of immune cell activity before and after Airnergy treatment
would be indicated to test this hypothesis.